Introduction of ertapenem into a hospital formulary: Effect on antimicrobial usage and improved in vitro susceptibility of Pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 12, 2009, Pages 5122-5126

  Goldstein, Ellie J C ^a,b   Citron, Diane M ^a   Peraino, Victoria ^b   Elgourt, Tanya ^b   Meibohm, Anne R ^c   Lu, Shuang ^c  

^a RM Alden Research Laboratory ^*  (United States)

^b SAINT JOHN'S HEALTH CENTER   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEFEPIME; CEFOTAXIME; ERTAPENEM; IMIPENEM; LEVOFLOXACIN; SULTAMICILLIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; DRUG EFFECT; DRUG FORMULARY; DRUG USE; HOSPITAL POLICY; HUMAN; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY;

AMPICILLIN; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; FORMULARIES, HOSPITAL; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; SULBACTAM;

EID: 71249146783     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00064-09     Document Type: Article

References (21)

1. Bratu, E. P., D. Landman, R. Haag, R. Recco, A. Eramo, M. Alam, and J. Quale. 2005. Rapid spread of single ribotype of KPC-producing, carbapenems-resistant Klebsiella pneumoniae in New York City. Ann. Intern. Med. 165:1430-1435.
2. Carmeli, Y., S. Lidji, E. Shsbsti, S. Navon-Venezia, and M. J. Schwaber. 2007. The effect of group 1 versus group 2 carbapenems on imipenem resistant P. aeruginosa: ecological study, abstr. K-396, p. 315. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother.
3. Crank, C. W., B. Hota, and J. Segreti. 2006. Effect of ertapenem utilization on Pseudomonas aeruginosa susceptibility to imipenem, abstr. 285, p. 99. Abstr. 44th Ann. Meet. Inf. Dis. Soc. Am.
4. Dellit, T. H, R. C. Owens, J. E. McGowan, Jr., D. N. Gerding, R. A. Weinstein, J. Burke, W. C. Huskins, D. L. Paterson, N. O. Fishman, C. F. Carpenter, P. J. Brennan, M. Billeter, and T. M. Hooton. 2007. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin. Infect. Dis. 44:159-177.
5. DiNubile, M. J., I. Friedland, C. Y. Chan, M. R. Motyl, H. Giezek, M. Shivaprakash, R. A. Weinstein, and J. P. Quinn. 2005. Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy. Eur. J. Clin. Microbiol. Infect. Dis. 24:443-449.
6. Fortaleza, C. M., M. P. Freire, D. de C. Filho, and M. de Caravalho Ramos. 2006. Risk factors for the recovery of imipenem- or ceftazidime-resistant Pseudomonas aeruginosa among patients admitted to a teaching hospital in Brazil. Infect. Control Hosp. Epidemiol. 27:901-906.
7. Gallant, A. R., and J. J. Goebel. 1976. Nonlinear regression with autoregressive errors. J. Am. Stat. Assoc. 71:961-967.
8. Goff, D. A., and J. E. Mangino. 2008. Ertapenem: no effect on aerobic gram-negative susceptibilities to imipenem. J. Infect. 57:123-127.
9. Hyle, E. P., A. D. Lipworth, T. E. Zaoutis, I. Nachamkin, W. B. Bilker, and E. Lautenbach. 2005. Impact of inadequate initial antimicrobial therapy on mortality in infections sue to extended-spectrum B-lactamase-producing Enterobacteriaceae. Ann. Intern. Med. 165:1375-1380.
10. Jones, R. N., D. J. Biedenbach, and A. C. Gales. 2003. Sustained activity and spectrum of selected extended-spectrum B-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000). Int. J. Antimicrob. Agents 21:1-7.
11. Lautenbach, E., M. G. Weine, I. Nachamkin, W. B. Bilker, A. Sheridan, and N. O. Fishman. 2006. Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect. Control Hosp. Epidemiol. 27:893-900.
12. Lima, A. L. L., P. R. Olivera, A. P. Paula, K. Dal-Paz, F. Rossi, and A. V. Zumiotti. 2009. The impact of ertapenem use on the susceptibility of Pseudomonas aeruginosa to imipenem: a hospital case study. Infect. Control Hosp. Epidemiol. 30:487-490.
13. Livermore, D. M., S. Mushtaq, and M. Warner. 2005. Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems. J. Antimicrob. Chemother. 55:306-311.
14. Neuhauser, M. M., R. A. Weinstein, R. Rydman, L. H. Danziger, G. Karam, and J. P. Quinn. 2003. Antibiotic resistance among gram-negative bacilli in US intensive care units. JAMA 289:885-888.
15. Paterson, D. L. 2006. Resistance in gram-negative bacteria: Enterobacteriaceae. Am. J. Infect. Control 34(Suppl. I):S20-S28.
16. Patterson, J. E. 2006. Multidrug-resistant gram-negative pathogens: multiple approaches and measures for prevention. Infect. Control Hosp. Epidemiol. 27:889-892.
17. Pfaller, M. A., and J. Segreti. 2006. Overview of the epidemiological profile and laboratory detection of extended-spectrum β-lactamases. Clin. Infect. Dis. 42(Suppl. 4):S153-S163.
18. Ramphal, R., and P. C. Ambrose. 2006. Extended-spectrum β-lactamases and clinical outcomes: current data. Clin. Infect. Dis. 42(Suppl. 4):S164-S172.
19. Shah, P., and R. D. Isaacs. 2003. Ertapenem, the first of a new group of carbapenems. J. Antimicrob. Chemother. 52:538-542.
20. SAS Institute. 1999. SAS/ETS 8 user's guide. SAS Institute, Cary, NC.
21. Shardell, M., A. D. Harris, S. S. El-Kamary, J. P. Furuno, R. R. Miller, and E. N. Perencevich. 2007. Statistical analysis and application of quasi experiments to antimicrobial resistance intervention studies. Clin. Infect. Dis. 45:901-907.